Following eight-and-a-half months of negotiations between Congress and the trade associations PhRMA and BIO, the expiring Prescription Drug User Fee Act (PDUFA), under which companies pay FDA to help support and speed up new drug approvals, has been reauthorized and expanded. For the first time, the bill provides a mechanism for risk management planning. The new PDUFA also requires FDA to turn to independent consultants to help resolve disputes over Phase III trial design.
The legislation was attached to the bioterrorism bill signed by President Bush, which calls for $1 billion in additional funding...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?